vedolizumab · Entyvio

Monoclonal antibody

Also known as MLN0002

Approvedregulatory verdict

Evidence outlook

Approved: Crohn's Disease, Ulcerative Colitis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (6)
CN
  • Adults with moderate to severe active ulcerative colitis or Crohn's disease with inadequate response, loss of response or intolerance to conventional therapy or TNFa inhibitors
Product first approved 2020takeda.com
JP
  • Adults with moderately to severely active Crohn's diseasetakeda.com
  • Moderately to severely active ulcerative colitistakeda.com
Product first approved 2018
CA
  • ENTYVIO® (vedolizumab) is indicated for: Ulcerative Colitis (Adults ≥ 18 years) the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, loss of response to, or were intolerant to either conventional therapy or infliximab, a tumor necrosis factor-alpha (TNFα) antagonist. Crohn's Disease (Adults ≥ 18 years) the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to immunomodulators or a TNFα antagonist; or have had an...
Product first approved 2015Health Canada
UK
  • Moderately to severely active ulcerative colitis and Crohn's disease
Product first approved 2014medicines.org.uk
EU
  • Moderately to severely active ulcerative colitis and Crohn's disease in adults (chronic pouchitis added later)
Product first approved 2014EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (31)
Crohn's Disease
NCT05837897 · Takeda
2023-06-16 – 2031-05-30 · Crohn's Disease
What this study did
NCT06227910 · Takeda
2025-01-02 – 2028-08-01 · Crohn's Disease
What this study did
NCT04779320 · Takeda
2022-02-10 – 2027-09-13 · Crohn's Disease (CD)
What this study did
Ulcerative Colitis
NCT05442567 · Takeda
2023-05-16 – 2033-02-07 · Ulcerative Colitis, Crohn's Disease
What this study did
NCT06405087 · Takeda
2025-10-27 – 2030-08-12 · Ulcerative Colitis, Crohn's Disease
What this study did
NCT06614387 · JAROSLAW KIERKUS
2024-10-01 – 2028-11-30 · Ulcerative Colitis
What this study did
NCT06100289 · Takeda
2025-01-22 – 2028-05-16 · Ulcerative Colitis, Crohn's Disease
What this study did
NCT03221036 · Takeda
2017-08-03 – 2028-01-30 · Moderately to Severely Active Ulcerative Colitis
What this study did
NCT04738942 · Takeda
2021-06-04 – 2027-11-30 · Ulcerative Colitis, Crohn's Disease
What this study did
NCT05771155 · Polpharma Biologics S.A.
2023-07-24 – 2025-09 · Ulcerative Colitis
What this study did
NCT04064697 · Centre Hospitalier Universitaire de Saint Etienne
2021-04-22 – 2024-02-08 · Ulcerative Colitis, Unspecified
What this study did
NCT04919252 · Yonsei University
2021-06-01 – 2023-01-31 · Crohn's Disease and Ulcerative Colitis
What this study did
NCT03035058 · Takeda
2017-02 – 2021-01 · Primary Sclerosing Cholangitis, Inflammatory Bowel Disease
What this study did
NCT02954159 · Medical College of Wisconsin
2017-05-18 – 2019-01-31 · Ulcerative Colitis
What this study did
Other / comorbidity
NCT06443502 · Takeda
2024-11-19 – 2030-01-31 · Pouchitis
What this study did
NCT05515029 · Federal Research Institute of Pediatric Hematology, Oncology and Immunology
2022-08-23 – 2026-10-16 · Acute Lymphoblastic Leukemia, Myeloblastic Leukemia, Biphenotypic Acute Leukemia, Malignant Lymphoma, Myelodysplastic Syndromes, Juvenile Myelomonocytic Leukemia
What this study did
NCT03657160 · Millennium Pharmaceuticals, Inc.
2019-02-06 – 2022-05-09 · Hematopoietic Stem Cells
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT06337695 · AHS Cancer Control Alberta
2026-08-13 – 2030-12-01 · IrAE, Immune-related Adverse Event, Diarrhea, Colitis
What this study did
Phase 2 (17)
Crohn's Disease
NCT03219359 · Aaron Etra
2018-02-22 – 2028-10 · Crohn Disease
What this study did
NCT02834754 · Marc Schwartz
2018-12-01 – 2019-05-01 · Crohn's Disease
What this study did
NCT00655135 · Millennium Pharmaceuticals, Inc.
2000-02 – 2002-06 · Crohn's Disease
What this study did
Ulcerative Colitis
NCT06850727 · Odyssey Therapeutics, Inc.
2025-06-02 – 2026-11 · Ulcerative Colitis (UC), UC - Ulcerative Colitis
What this study did
NCT03196427 · Takeda
2018-07-30 – 2025-07-17 · Ulcerative Colitis, Crohn's Disease
What this study did
NCT03138655 · Takeda
2017-11-08 – 2020-05-26 · Ulcerative Colitis, Crohn's Disease
What this study did
NCT02913508 · Takeda
2014-04 – 2015-12 · Ulcerative Colitis, Crohn's Disease
What this study did
NCT00619489 · Millennium Pharmaceuticals, Inc.
2007-12 – 2010-03 · Ulcerative Colitis, Crohn's Disease
What this study did
NCT01177228 · Millennium Pharmaceuticals, Inc.
2007-05 – 2008-09 · Ulcerative Colitis
What this study did
Other / comorbidity
NCT06815003 · City of Hope Medical Center
2025-04-18 – 2028-10-15 · Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Graft Versus Host Disease, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
What this study did
NCT06841705 · Shilpa Grover, MD, MPH
2025-07-15 – 2026-12-31 · Immune Checkpoint Inhibitor-Related Colitis
What this study did
NCT06317220 · Massachusetts General Hospital
2024-12-03 – 2026-10 · Collagenous Gastritis
What this study did
NCT04797325 · University of Copenhagen
2021-08-30 – 2025-04 · Immune-Mediated Colitis
What this study did
NCT03147859 · Ottawa Hospital Research Institute
2017-11-01 – 2023-12-31 · HIV-infection/AIDS
What this study did
NCT04120415 · ANRS, Emerging Infectious Diseases
2022-06-21 – 2023-07-12 · HIV-1-infection
What this study did
NCT02929316 · AGA Clinical Research Associates, LLC
2018-06-25 – 2018-10-05 · Celiac Disease
What this study did
NCT02993783 · Millennium Pharmaceuticals, Inc.
2017-04-28 – 2018-05-09 · Allogeneic Hematopoietic Stem Cell Transplantation
What this study did
Phase 1/2 (3)
Other / comorbidity
NCT04407247 · M.D. Anderson Cancer Center
2020-07-09 – 2027-12-31 · Colitis, Lung Non-Small Cell Carcinoma, Malignant Genitourinary System Neoplasm, Malignant Solid Neoplasm, Melanoma
What this study did
NCT03577782 · Hospitales Universitarios Virgen del Rocío
2018-09 – 2020-05 · HIV Infections
What this study did
NCT02972450 · ANRS, Emerging Infectious Diseases
2019-02-20 – 2019-07-11 · HIV-1-infection
What this study did
Phase 1 (14)
Crohn's Disease
NCT02953275 · University of Miami
2017-04-13 – 2019-06-13 · Crohn Disease
What this study did
Ulcerative Colitis
NCT04112212 · University Medical Center Groningen
2020-11-04 – 2023-01-01 · Crohn Disease, Colitis, Ulcerative
What this study did
NCT03309865 · Mayo Clinic
2017-12-25 – 2018-12-31 · Ulcerative Colitis, Dietary Modification
What this study did
NCT03329209 · Takeda
2018-03-05 – 2018-09-05 · Colitis, Ulcerative, Crohn Disease
What this study did
NCT01981616 · Millennium Pharmaceuticals, Inc.
2011-09 – 2012-07 · Inflammatory Bowel Disease
What this study did
Other / comorbidity
NCT05281614 · Benaroya Research Institute
2022-09-21 – 2024-01-10 · Type 1 Diabetes
What this study did
NCT02788175 · National Institute of Allergy and Infectious Diseases (NIAID)
2016-05-28 – 2019-03-04 · HIV
What this study did
NCT02728895 · Takeda
2016-06-15 – 2018-07-10 · Allogeneic Hematopoietic Stem Cell Transplantation
What this study did
Phase 4 (34)
Crohn's Disease
NCT06257706 · Alimentiv Inc.
2024-08-07 – 2029-02-06 · Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn
What this study did
NCT05928039 · University of Calgary
2023-10-25 – 2028-12-31 · Crohn Disease
What this study did
NCT06045754 · Takeda
2024-04-18 – 2027-06-28 · Crohn's Disease
What this study did
NCT03142321 · Washington University School of Medicine
2018-06-08 – 2024-10-28 · Crohn Disease of Small Intestine
What this study did
NCT02646683 · Geert D'Haens
2015-07 – 2023-05-26 · Crohn Disease
What this study did
NCT02768532 · Centre Hospitalier Universitaire de Saint Etienne
2016-07-01 – 2023-01-23 · Crohn Disease
What this study did
NCT02764762 · Takeda
2017-04-18 – 2022-07-05 · Crohn Disease
What this study did
NCT02820493 · Universita degli Studi di Genova
2016-09 – 2019-03 · Crohn Disease
What this study did
NCT02630966 · Takeda
2016-08-10 – 2018-11-14 · Crohn's Disease
What this study did
NCT02324699 · Icahn School of Medicine at Mount Sinai
2016-04 – 2018-02-08 · Crohn's Disease
What this study did
Ulcerative Colitis
NCT07576452 · University Hospital, Clermont-Ferrand
2026-12-01 – 2030-12-01 · Ulcerative Colitis (UC)
What this study did
NCT06788340 · Odense University Hospital
2026-01-23 – 2028-11-30 · Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
What this study did
NCT06581328 · Takeda
2025-03-27 – 2028-06-01 · Ulcerative Colitis, Crohn's Disease
What this study did
NCT06609447 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2024-09-21 – 2027-12-31 · Ulcerative Colitis
What this study did
NCT06095128 · Takeda
2024-06-12 – 2027-07-09 · Ulcerative Colitis
What this study did
NCT06584162 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2023-02-09 – 2026-02-01 · Inflammatory Bowel Diseases
What this study did
NCT05481619 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2021-01-01 – 2026-01-01 · Ulcerative Colitis
What this study did
NCT04743518 · Centre Hospitalier Universitaire, Amiens
2021-02-02 – 2025-12 · Ulcerative Colitis
What this study did
NCT06626165 · Showa Inan General Hospital
2024-07-20 – 2025-09-30 · Ulcerative Colitis
What this study did
NCT03679546 · Rennes University Hospital
2019-01-04 – 2025-06-16 · Ulcerative Colitis
What this study did
NCT07398586 · Second Affiliated Hospital of Wenzhou Medical University
2020-01-01 – 2024-12-31 · Ulcerative Colitis (UC)
What this study did
NCT04804540 · Takeda
2021-12-08 – 2024-02-02 · Ulcerative Colitis, Crohn Disease
What this study did
NCT02743806 · Takeda
2016-08-01 – 2023-01-03 · Colitis, Ulcerative, Crohn Disease
What this study did
NCT03629379 · Universitaire Ziekenhuizen KU Leuven
2019-01-22 – 2021-07-01 · Inflammatory Bowel Diseases, Psoriasis
What this study did
NCT03029143 · Takeda
2017-03-29 – 2020-10-16 · Colitis, Ulcerative
What this study did
NCT02760615 · Takeda
2016-11-01 – 2020-08-01 · Colitis, Ulcerative, Crohn Disease
What this study did
NCT02646657 · Geert D'Haens
2015-07 – 2020-08 · Colitis, Ulcerative
What this study did
NCT04006080 · Guy's and St Thomas' NHS Foundation Trust
2019-07-01 – 2020-03 · Ulcerative Colitis
What this study did
NCT02559713 · Takeda
2017-11-29 – 2019-02-22 · Colitis, Ulcerative, Crohn's Disease
What this study did
NCT03237260 · University of Pennsylvania
2017-07-01 – 2019-02-01 · Ulcerative Colitis
What this study did
Other / comorbidity
NCT06031233 · Isala
2023-09-01 – 2028-12 · Oncology, Infusion Reaction
What this study did
NCT06066840 · The First Affiliated Hospital of Soochow University
2022-08-01 – 2025-12-31 · Safety and Efficacy
What this study did
NCT02790138 · Takeda
2016-10-12 – 2021-02-02 · Pouchitis
What this study did
Early phase / not applicable (5)
Crohn's Disease
NCT03889613 · Sheba Medical Center
2019-04-03 – 2024-11-01 · Crohn Disease
What this study did
NCT04328922 · Tel-Aviv Sourasky Medical Center
2018-07-03 – 2023-01 · Crohn Disease, Microbial Substitution
What this study did
Ulcerative Colitis
NCT02862132 · Shaare Zedek Medical Center
2017-01 – 2022-01 · Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Disease
What this study did
NCT02878083 · Nantes University Hospital
2017-01-11 – 2021-01-01 · ULCERATIVE COLITIS
What this study did
Other / comorbidity
NCT02694588 · University Hospital Schleswig-Holstein
2014-06 – 2021-12 · IBD
What this study did
Used as active comparator (7)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (2)
Ulcerative Colitis
NCT06570772 · Alvotech Swiss AG
2024-09-23 – 2025-11-25 · Ulcerative Colitis
What this study did
NCT04469062 · Eli Lilly and Company
2021-04-20 – 2024-06-05 · Ulcerative Colitis
What this study did
Phase 2 (4)
Ulcerative Colitis
Other / comorbidity
NCT07619898 · Therakos LLC
2026-07 – 2029-12 · Colitis, Hepatitis, Melanoma (Skin Cancer)
What this study did
NCT06646016 · Therakos LLC
2025-12-15 – 2027-02-19 · Immune-related Colitis
What this study did
NCT05132166 · University Health Network, Toronto
2021-12-22 – 2026-04-26 · Graft Vs Host Disease
What this study did
Phase 1 (1)
Other / comorbidity
NCT06732804 · Alvotech Swiss AG
2025-02-11 – 2026-01-08 · Healthy Male and Female Subjects
What this study did
Studied as part of a combination product (1)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 2/3 (1)
Other / comorbidity
NCT06475820 · Federal Research Institute of Pediatric Hematology, Oncology and Immunology
2023-12-01 – 2027-04-01 · Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Biphenotypic Acute Leukemia, Malignant Lymphoma, Myelodysplastic Syndromes
What this study did
Appears in other studies (5)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 1 (1)
Other / comorbidity
NCT03819296 · M.D. Anderson Cancer Center
2021-02-21 – 2026-10-31 · Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage IIA Cutaneous Melanoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Colitis, Lung Non-Small Cell Carcinoma, Malignant Genitourinary System Neoplasm, Malignant Solid Neoplasm, Pathologic Stage 0 Cutaneous Melanoma AJCC v8, Pathologic Stage I Cutaneous Melanoma AJCC v8, Pathologic Stage IA Cutaneous Melanoma AJCC v8, Pathologic Stage IB Cutaneous Melanoma AJCC v8, Pathologic Stage II Cutaneous Melanoma AJCC v8, Pathologic Stage IIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIC Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Stage 0 Lung Cancer AJCC v8, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
Phase 4 (3)
Ulcerative Colitis
NCT07665294 · Ryan C Ungaro
2026-10-01 – 2027-06-23 · Ulcerative Colitis
What this study did
NCT05205603 · Sixth Affiliated Hospital, Sun Yat-sen University
2022-01-15 – 2025-01-15 · Ulcerative Colitis, Efficacy, Self, Biologics, Mesalazine
What this study did
NCT03885713 · Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
2019-09-10 – 2024-12-31 · Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
What this study did
Early phase / not applicable (1)
Ulcerative Colitis
NCT06095596 · Sixth Affiliated Hospital, Sun Yat-sen University
2023-11-01 – 2026-10-31 · Ulcerative Colitis (UC)
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Ulcerative Colitis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Vedolizumab (Entyvio): this drugApprovedMonoclonal antibodyα4β7 integrinReliable signal
NCT02497469: Percentage of Participants Who Achieved Clinical Remission (Week 52): Adalimumab SC, 160/80/40 mg 22.5% (95% CI 18.5-27.0) vs Vedolizumab IV 300 mg 31.3% (95% CI 26.7-36.2); p=0.0061 (Adalimumab SC, 160/80/40 mg vs Vedolizumab IV 300 mg)
NCT02611830: Percentage of Participants Achieving Clinical Remission at Week 52 (Week 52): Maintenance Phase: Induction IV + Placebo 14.3% (95% CI 6.4-26.2) vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC 46.2% (95% CI 36.5-56.2) vs Maintenance Phase: Induction IV + Vedolizumab 300 mg IV 42.6% (95% CI 29.2-56.8); p=<0.001 (Maintenance Phase: Induction IV + Placebo vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC)
Adalimumab (Humira)ApprovedMonoclonal antibodyTNF-alphaPartial signal
NCT00408629: Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8 (Week 8): Adalimumab 160/80/40 16.5% vs Placebo 9.3%; p=0.019 (Adalimumab 160/80/40 vs Placebo)
NCT02065557: Induction (Week 8, ITT-E, Main Study): I-SD 43.3% vs external placebo 19.83% (p=0.382, NS); I-HD 59.6% vs external placebo (p<0.001); combined I-SD+I-HD 53.2% (p<0.001). Maintenance (Week 52, mITT-E): M-PL 33.3% (n=12, descriptive only); M-SD 29.0% vs external placebo 18.37% (p=0.382, NS); M-HD 45.2% (p<0.001); combined M-SD+M-HD 37.1% (p<0.001).
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Balsalazide Disodium (Colazal)
ApprovedUS marketing discontinued
Small moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Budesonide (Uceris Rectal Foam)ApprovedSmall moleculeGlucocorticoid receptorReliable signalNo reviewed efficacy summary in this indication
Budesonide MMX (Uceris)ApprovedSmall moleculeGlucocorticoid receptorPartial signal
NCT01532648: Registered primary, clinical remission at day 56 (UCDAI rectal bleeding and stool frequency subscores of 0), budesonide MMX 9 mg vs placebo added to oral mesalamine: 56/230 vs 52/228 (CT.gov); similar in both groups, p=0.70 (Rubin 2017). Combined clinical and endoscopic remission at week 8: 13.0% vs 7.5%, p=0.049. missed
DexamethasoneApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Etrasimod (Velsipity)ApprovedSmall moleculeS1P receptorReliable signal
NCT03945188: Percentage of Participants Achieving Clinical Remission at Week 12 (At Week 12): Etrasimod 2 mg 27.0% vs Placebo 7.4%; p=<0.001 (Etrasimod 2 mg vs Placebo)
NCT03996369: Percentage of Participants Achieving Clinical Remission (Week 12): Etrasimod 2 mg 24.8% vs Placebo 15.2%; p==0.026 (Etrasimod 2 mg vs Placebo)
Golimumab (Simponi)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT01863771: Number of Participants Who Achieved Clinical Response Through Maintenance-Week 54 Measured Using the Mayo Score (Up to Week 54): Placebo 6/31 (19.4%) (95% CI 5.4-33.3) vs Golimumab 18/32 (56.3%) (95% CI 39.1-73.4)
NCT00488631: Number of Participants in Clinical Response Through Week 54 (Induction Baseline, Week 0 through Week 54): Golimumab Induction Responders (GLM-I-Rsp)-Placebo Maintenance 48/154 (31.2%) vs GLM-I-Rsp-Golimumab 50 mg Maintenance 71/151 (47.0%) vs GLM-I-Rsp-Golimumab 100 mg Maintenance 75/151 (49.7%); p=0.010 (Golimumab Induction Responders (GLM-I-Rsp)-Placebo Maintenance vs GLM-I-Rsp-Golimumab 50 mg Maintenance), p=<0.001 (Golimumab Induction Responders (GLM-I-Rsp)-Placebo Maintenance vs GLM-I-Rsp-Golimumab 100 mg Maintenance)
Guselkumab (Tremfya)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT05528510: Percentage of Participants in Clinical Remission at Week 12 (Week 12): Placebo 6.5 Percentage of participants (95% CI 2.4 to 10.6) | Combined Guselkumab 400 mg 27.6 Percentage of participants (95% CI 22.4 to 32.8)
QUASAR/GALAXI: superior to ustekinumab on pooled endoscopic endpoints
Hydrocortisone (Cortenema)ApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Hydrocortisone Acetate (Cortifoam)ApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Infliximab (Remicade)ApprovedMonoclonal antibodyTNF-alphaWeak signal
NCT01585155: Percent of Patients Who Achieved CAI Remission (Weeks 2, 6, 8, 10, 14, 18, 22, 26, 30, and the last time point during the period from administration of the study drug to Week 30): TA-650 — Weeks 2: 60%; Weeks 6: 80%; Weeks 8: 80%; Weeks 10: 77.8%; Weeks 14: 87.5%; Weeks 18: 87.5%; Weeks 22: 64.3%; Weeks 26: 85.7%; Weeks 30: 64.3%; The last time point: 42.9%
NCT00336492: The Number of Participants With Clinical Response at Week 8 (Week 8): Infliximab 5 mg/kg 44/60 (73.3%)
Infliximab-Abda (Renflexis)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Axxq (Avsola)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Dyyb (Inflectra)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Dyyb (Zymfentra)ApprovedMonoclonal antibodyTNF-alphaReliable signalNo reviewed efficacy summary in this indication
Infliximab-Qbtx (Ixifi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Mesalamine (Apriso)ApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Mesalamine (Canasa)ApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Mesalamine (Lialda)ApprovedSmall moleculeAminosalicylateReliable signal
NCT00151892: Endoscopic Remission of Ulcerative Colitis (UC) at 6 Months (6 Months): SPD476 83.7 percent of participants | Asacol 81.5 percent of participants
Mesalamine (Pentasa)ApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Mesalamine (Rowasa)ApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
MethylprednisoloneApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Mirikizumab (Omvoh)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT03524092: Percentage of Participants in Clinical Remission at Week 40 (Mirikizumab Induction Responders) (Week 40): Maintenance Period: Miri IR - 200 mg Miri SC 49.9% (95% CI 44.7 to 55) vs Maintenance Period: Miri IR - PBO SC 25.1% (95% CI 18.8 to 31.5)
NCT03518086: Percentage of Participants With Clinical Remission at Week 12 (Week 12): Placebo IV Q4W 13.3% (95% CI 6.9-19.6) vs 300 mg Mirikizumab IV Q4W 24.2% (95% CI 19.5-28.9); p=0.00006 (Placebo IV Q4W vs 300 mg Mirikizumab IV Q4W)
Olsalazine (Dipentum)ApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Ozanimod (Zeposia)ApprovedSmall moleculeS1P receptorReliable signal
NCT02435992: Percentage of Participants in Clinical Remission at 10 Weeks (At 10 Weeks): RPC1063 Cohort 1(Induction Period) 18.4% vs Placebo Cohort 1 (Induction Period) 6.0% vs RPC1063 Cohort 2 (Induction Period) 21.0%; p=0.0001 (RPC1063 Cohort 1(Induction Period) vs Placebo Cohort 1 (Induction Period))
NCT03915769: Clinical response at week 12: 52.9% (0.46 mg) and 61.5% (0.92 mg) vs 32.3% placebo.
Risankizumab (Skyrizi)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
INSPIRE/COMMAND: clinical remission + endoscopic improvement met
NCT03398148: Sub-Study 1: Percentage of Participants Achieving Clinical Remission Per Adapted Mayo Score (Week 12): Substudy 1, Induction Period 1: Double-blind Placebo IV 1/60 (1.7%) vs Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV 7/61 (11.5%) vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV 6/61 (9.8%) vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV 6/58 (10.3%) vs Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV 42/340 (12.4%); p=0.0324 (Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV), p=0.0460 (Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV), p=0.0397 (Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV)
SulfasalazineApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Tofacitinib (Xeljanz)ApprovedSmall moleculeJAK, JAK1/JAK3Reliable signal
NCT01458574: Percentage of Participants In Remission at Week 52 (Week 52): Tofacitinib 5 mg BID 34.3% vs Tofacitinib 10 mg BID 40.6% vs Placebo 11.1%; p=<0.0001 (Tofacitinib 5 mg BID vs Placebo), p=<0.0001 (Tofacitinib 10 mg BID vs Placebo)
NCT01458951: Percentage of Participants With Remission at Week 8 (Week 8): Tofacitinib 10 mg BID 16.6% vs Placebo BID 3.6%; p=0.0005 (Tofacitinib 10 mg BID vs Placebo BID)
Upadacitinib (Rinvoq)ApprovedSmall moleculeJAK, JAK1Reliable signal
NCT03653026: Percentage of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8 (Week 8): Upadacitinib 45 mg 33.5% (95% CI 28.5-38.5) vs Placebo 4.1% (95% CI 1.1-7.1); p=<0.001 (Upadacitinib 45 mg vs Placebo)
NCT02819635: Substudy 1: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8 (At Week 8): SS1: Placebo 0% vs SS1: Upadacitinib 7.5 mg 8.5% vs SS1: Upadacitinib 15 mg 14.3% vs SS1: Upadacitinib 30 mg 13.5% vs SS1: Upadacitinib 45 mg 21.4%; p=0.049 (SS1: Placebo vs SS1: Upadacitinib 7.5 mg), p=0.010 (SS1: Placebo vs SS1: Upadacitinib 15 mg), p=0.007 (SS1: Placebo vs SS1: Upadacitinib 30 mg), p=<0.001 (SS1: Placebo vs SS1: Upadacitinib 45 mg)
Ustekinumab (Stelara)ApprovedMonoclonal antibodyIL-12 p40Reliable signal
NCT02407236: Induction Study - Number of Participants With Clinical Remission at Week 8 (As Per Global Definition) (Week 8): Induction Study (IS): Placebo Intravenous (IV) 17/319 (5.3%) vs IS: Ustekinumab 130 Milligram (mg) IV 50/320 (15.6%) vs IS: Ustekinumab Approximately 6 mg/kg IV 50/322 (15.5%); p=< 0.001 (Induction Study (IS): Placebo Intravenous (IV) vs IS: Ustekinumab 130 Milligram (mg) IV), p=< 0.001 (Induction Study (IS): Placebo Intravenous (IV) vs IS: Ustekinumab Approximately 6 mg/kg IV)
NCT04630028: Week 8 clinical remission 25% (27/107) after IV induction; the study's primary endpoint is week 52 remission in week 8 responders.
Ustekinumab-Aauz (Otulfi)Approved—IL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Aekn (Selarsdi)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Auub (Wezlana)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Hmny (Starjemza)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Srlf (Imuldosa)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Stba (Steqeyma)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Ttwe (Pyzchiva)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Mesalamine (Asacol HD)US approval withdrawnSmall moleculeAminosalicylatePartial signalNo reviewed efficacy summary in this indication
AfimkibartPhase 3Monoclonal antibodyTL1APartial signal
NCT04090411: Induction Period: Percentage of Participants Who Achieved Clinical Remission at Week 14 (At Week 14): Induction Period: Placebo 11.6% (95% CI 5.77-22.88) vs Induction Period: PF-06480605 50 mg 25.5% (95% CI 15.44-37.19) vs Induction Period: PF-06480605 150 mg 23.3% (95% CI 14.98-33.98) vs Induction Period: PF-06480605 450 mg 23.9% (95% CI 16.58-32.06); p=0.0545 (Induction Period: Placebo vs Induction Period: PF-06480605 50 mg), p=0.0823 (Induction Period: Placebo vs Induction Period: PF-06480605 150 mg), p=0.0642 (Induction Period: Placebo vs Induction Period: PF-06480605 450 mg) missed
DuvakitugPhase 3Monoclonal antibodyTL1APartial signal
NCT05499130: UC cohort, clinical remission at week 14: 36% (450 mg) / 48% (900 mg) vs 20% placebo, placebo-adjusted 16% (p=.050) / 27% (p=.003). CD cohort, endoscopic response: 26.1% (low dose) / 47.8% (high dose) vs 13.0% placebo. P-values are one-sided at a 0.10 significance level.
Icotrokinra (Icotyde)Phase 3PeptideIL-23 receptorReliable signal
NCT06049017: Primary endpoint clinical response at Week 12: 63.5% with the highest icotrokinra dose vs 27% with placebo (p<0.001)
JNJ-78934804Phase 3CombinationIL-23 p19, TNF-alphanot yet gradedNo reviewed efficacy summary in this indication
MufemilastPhase 3Small moleculePDE4not yet gradedNo reviewed efficacy summary in this indication
ObefazimodPhase 3Small moleculemiR-124Reliable signal
NCT05535946: ABTECT maintenance, clinical remission at Week 44: placebo 10.4% (20), 25 mg 50.8% (98; placebo-adjusted +39.3%), 50 mg 51.3% (100; placebo-adjusted +40.3%), p<0.0001
NCT05507203: ABTECT-1 (NCT05507203), clinical remission at Week 8: placebo 2.5% (4/158), 25 mg 23.8% (38/160, p<0.0001), 50 mg 21.7% (69/318, p<0.0001; placebo-adjusted +19.3%)
PonesimodPhase 3Small moleculeS1P receptornot yet gradedNo reviewed efficacy summary in this indication
TulisokibartPhase 3Monoclonal antibodyTL1AReliable signal
NCT06052059: ATLAS-UC Study 2 (NCT06052059): tulisokibart met its primary endpoint of clinical remission (Modified Mayo Score) at week 12, plus key secondary endpoints.
NCT04996797: Remission 26% vs 1% placebo; +25pp (95% CI 14–37)
AC-101Phase 2Small moleculeRIPK2not yet gradedNo reviewed efficacy summary in this indication
ALTB-268Phase 2Monoclonal antibodyPSGL-1Weak signalNo reviewed efficacy summary in this indication
AmiselimodPhase 2Small moleculeS1P receptorReliable signal
NCT04857112: Change from baseline in modified Mayo Score at Day 85: amiselimod -2.3 vs placebo -1.6 (p=0.002)
ATH-063Phase 2Small moleculeG9A (EHMT2)Weak signalFeatured results are safety only in this race
HRS-7085Phase 2Small moleculeNCBP1/NCBP2 (nuclear cap-binding complex)Weak signalNo reviewed efficacy summary in this indication
IPG11406Phase 2Small moleculeEBI2Weak signalFeatured results are safety only in this race
MT-201Phase 2Biologic (subtype unspecified)—not yet gradedNo reviewed efficacy summary in this indication
MT-501Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
OmilancorPhase 2Small moleculeLANCL2Partial signal
NCT03861143: Clinical Remission (Week 12): BT-11 Low-dose (440 mg) 30.3% | BT-11 High-dose (880 mg) 31.8% vs Placebo 22.7%
SPY001Phase 2Monoclonal antibodyα4β7 integrinnot yet gradedNo reviewed efficacy summary in this indication
Trosunilimab
Phase 2(overall)
Monoclonal antibodyα4β7 integrin
Partial signal(overall)
No reviewed efficacy summary in this indication
ZotemtegrastPhase 2Small moleculeα4β7 integrinWeak signal
NCT05611671: Percentage of Participants in Clinical Remission as Determined Using the Modified Mayo Clinic Score (mMCS) (Week 12): MORF-057 200 mg BID 31.9% | MORF-057 100 mg BID 23.9% | MORF-057 100 mg QD-M 17.1% vs Placebo 24.3% missed
NCT05291689: Main Cohort: Change From Baseline to Week 12 in the Robarts Histopathology Index (RHI) Score (From baseline to 12 weeks): MORF-057 (Main Cohort) -6.4 score on a scale (Standard Deviation 11.18)
ICG318Phase 1/2Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
Remestemcel-L (Ryoncil)Phase 1/2Cell therapyAllogeneic MSC therapynot yet gradedNo reviewed efficacy summary in this indication
BDHK-2009Phase 1Small molecule—not yet gradedNo reviewed efficacy summary in this indication
ExoFloPhase 1Cell therapyMSC-derived exosomesWeak signalNo reviewed efficacy summary in this indication

Large race: only the 72 furthest-along competitors are listed; 43 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(24 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Entyvio (vedolizumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (12)
May 2027 (1)
Phase 4Crohn's DiseaseRecruiting
Est. primary completion 2027-05-01 · NCT06581328 · CT.gov ↗
What to watch
June 2027 (2)
Phase 3Crohn's DiseaseRecruiting
Est. primary completion 2027-06-08 · NCT06227910 · CT.gov ↗
What to watch
Phase 4Crohn's DiseaseActive not recruiting
Est. primary completion 2027-06-28 · NCT06045754 · CT.gov ↗
What to watch
July 2027 (2)
Phase 4Ulcerative ColitisActive not recruiting
Est. primary completion 2027-07-09 · NCT06095128 · CT.gov ↗
What to watch
Phase 4Crohn's DiseaseRecruiting
Est. primary completion 2027-07-30 · NCT05928039 · CT.gov ↗
What to watch
August 2027 (1)
Phase 3Ulcerative ColitisActive not recruiting
Est. primary completion 2027-08 · NCT06880744 · CT.gov ↗
What to watch
September 2027 (2)
Phase 3Crohn's DiseaseRecruiting
Est. primary completion 2027-09-13 · NCT04779320 · CT.gov ↗
What to watch
Phase 3Ulcerative ColitisActive not recruiting
Est. primary completion 2027-09-24 · NCT03221036 · CT.gov ↗
What to watch
October 2027 (1)
Phase 4Crohn's DiseaseRecruiting
Est. primary completion 2027-10-31 · NCT06180382 · CT.gov ↗
What to watch
December 2027 (3)
Phase 4Crohn's DiseaseEnrolling by invitation
Est. primary completion 2027-12-30 · NCT06788340 · CT.gov ↗
What to watch
Phase 1/2Colitis, Lung Non-Small Cell Carcinoma, Malignant Genitourinary System Neoplasm, Malignant Solid Neoplasm, MelanomaActive not recruiting
Est. primary completion 2027-12-31 · NCT04407247 · CT.gov ↗
What to watch
Phase 4Ulcerative ColitisRecruiting
Est. primary completion 2027-12-31 · NCT06609447 · CT.gov ↗
What to watch
2028 (5)
April 2028 (1)
Phase 3Ulcerative ColitisNot yet recruiting
Est. primary completion 2028-04-30 · NCT06614387 · CT.gov ↗
What to watch
May 2028 (1)
Phase 3Crohn's DiseaseRecruiting
Est. primary completion 2028-05-16 · NCT06100289 · CT.gov ↗
What to watch
July 2028 (1)
Phase 4Oncology, Infusion ReactionRecruiting
Est. primary completion 2028-07 · NCT06031233 · CT.gov ↗
What to watch
October 2028 (2)
Phase 2Crohn's DiseaseRecruiting
Est. primary completion 2028-10 · NCT03219359 · CT.gov ↗
What to watch
Phase 2Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Graft Versus Host Disease, Myelodysplastic Syndrome …Recruiting
Est. primary completion 2028-10-15 · NCT06815003 · CT.gov ↗
What to watch
2029 (1)
January 2029 (1)
Phase 4Crohn's DiseaseRecruiting
Est. primary completion 2029-01-03 · NCT06257706 · CT.gov ↗
What to watch
2030 (5)
January 2030 (1)
Phase 3PouchitisRecruiting
Est. primary completion 2030-01-31 · NCT06443502 · CT.gov ↗
What to watch
March 2030 (1)
Phase 3Crohn's DiseaseRecruiting
Est. primary completion 2030-03-08 · NCT05837897 · CT.gov ↗
What to watch
June 2030 (1)
Phase 4Ulcerative ColitisNot yet recruiting
Est. primary completion 2030-06-01 · NCT07576452 · CT.gov ↗
What to watch
August 2030 (1)
Phase 3Crohn's DiseaseRecruiting
Est. primary completion 2030-08-12 · NCT06405087 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2/3IrAE, Immune-related Adverse Event, Diarrhea, ColitisRecruiting
Est. primary completion 2030-12-01 · NCT06337695 · CT.gov ↗
What to watch
2033 (1)
February 2033 (1)
Phase 3Crohn's DiseaseRecruiting
Est. primary completion 2033-02-07 · NCT05442567 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

Q1 2027FDA action datePDUFA goal date set for Q1 2027
US, FDA · Source ↗

Recent

9 June 2026Filing acceptedFDA accepts sBLA for IV Entyvio in pediatric UC and Crohn's disease
US, FDA · Source ↗